Edwards Lifesciences (NYSE:EW) Upgraded at Daiwa America

Edwards Lifesciences (NYSE:EW) was upgraded by investment analysts at Daiwa America to a “strong-buy” rating in a report issued on Wednesday, Zacks.com reports.

A number of other equities analysts have also recently commented on EW. Citigroup lifted their price target on shares of Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Robert W. Baird lowered shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $102.00 to $70.00 in a report on Thursday, July 25th. Truist Financial lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $110.00 to $82.00 in a report on Thursday, July 25th. Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday. Fourteen investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.10.

Edwards Lifesciences Price Performance

EW stock opened at $61.86 on Wednesday. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average price of $85.87 and a 200 day moving average price of $86.50. The stock has a market cap of $37.28 billion, a PE ratio of 26.66, a P/E/G ratio of 2.64 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period in the previous year, the company earned $0.66 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Equities research analysts anticipate that Edwards Lifesciences will post 2.71 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were acquired at an average cost of $85.74 per share, with a total value of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,099 shares of company stock valued at $2,680,879. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently made changes to their positions in the company. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $28,000. First Community Trust NA acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $29,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $34,000. DSM Capital Partners LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. Finally, Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $39,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.